Farkasgyepui Tudogyogyintezet
- Address
- lock Available on a paid plan
Farkasgyepui Tudogyogyintezet - Advanced Lung Cancer Research Center
Farkasgyepui Tudogyogyintezet is a specialized pulmonary research institution dedicated to advancing the treatment of lung cancers through participation in cutting-edge clinical trials. The center focuses primarily on novel therapeutic approaches for non-small cell lung cancer (NSCLC) and small cell lung cancer, with particular expertise in immunotherapy combinations and targeted therapies for patients with specific genomic mutations.
- Advanced and metastatic NSCLC with KRAS G12C mutations, HER2 mutations, and other actionable genomic alterations
- Immunotherapy combinations including pembrolizumab, durvalumab, and novel checkpoint inhibitors in various treatment settings
- Early-stage and resectable NSCLC with neoadjuvant and adjuvant treatment strategies
- Chronic obstructive pulmonary disease (COPD) and relapsed small cell lung cancer
The institution demonstrates significant expertise in evaluating antibody-drug conjugates (ADCs) such as datopotamab deruxtecan and next-generation targeted therapies including adagrasib and zongertinib. Their research portfolio encompasses the full spectrum of lung cancer care, from perioperative immunotherapy in resectable disease to first-line and relapsed settings in advanced stages. The center's participation in multiple Phase 2 and Phase 3 randomized trials positions it at the forefront of personalized medicine approaches for lung cancer patients, particularly those with PD-L1 expression variations and specific molecular profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Farkasgyepui Tudogyogyintezet
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis | CSL Behring LLC | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 15 | Unknown | 2015-11-06 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.